List of Oraverse drug patents

Oraverse is owned by Septodont Holding.

Oraverse contains Phentolamine Mesylate.

Oraverse has a total of 3 drug patents out of which 0 drug patents have expired.

Oraverse was authorised for market use on 09 May, 2008.

Oraverse is available in injectable;injection dosage forms.

Oraverse can be used as a method of reversing soft-tissue anesthesia i.e. anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic.

The generics of Oraverse are possible to be released after 21 April, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7229630 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Jun, 2023

(4 months from now)

US7569230 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Oct, 2023

(8 months from now)

US7575757 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Apr, 2025

(2 years from now)

Drugs and Companies using PHENTOLAMINE MESYLATE ingredient

Market Authorisation Date: 09 May, 2008

Treatment: A method of reversing soft-tissue anesthesia i.e. anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic

Dosage: INJECTABLE;INJECTION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic